{"commentary":{"count":148,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":66,"youtube":50,"podcast":28,"x_video":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05572515\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MajesTEC-9","nct_id":"NCT05572515","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=majestec-9-nct05572515. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"MajesTEC-9","arms":[{"description":"Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2.","label":"Teclistamab","type":"EXPERIMENTAL"},{"description":"Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study.","label":"Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-08-31","type":"ESTIMATED"},"conditions":["Relapsed or Refractory Multiple Myeloma"],"enrollment":{"count":614,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Teclistamab","type":"DRUG"},{"name":"Pomalidomide","type":"DRUG"},{"name":"Bortezomib","type":"DRUG"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Carfilzomib","type":"DRUG"}],"last_update":"2026-04-13","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-10-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Progression-free Survival (PFS)","timeFrame":"Up to 9 years"},{"measure":"Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity","timeFrame":"Up to 9 years"}],"references":[{"citation":"Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, Botta C, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegard M, Wang D, Pei L, Wroblewski S, Aries IM, Quijano Carde NA, Perova T, de Jager T, Yeh TM, Vanquickelberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O; MajesTEC-9 Trial Investigators. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. N Engl J Med. 2026 Jul 30;395(5):440-453. doi: 10.1056/NEJMoa2603870. Epub 2026 May 29.","pmid":"42212933","type":"DERIVED"}],"start_date":{"date":"2023-03-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05572515"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/majestec-9-nct05572515"}